Search Results - "Oulès, Valérie"

Occult Hepatitis C Virus Infection Revisited with Ultrasensitive Real-Time PCR Assay by Halfon, Philippe, Bourlière, Marc, Ouzan, Denis, Sène, Damien, Saadoun, David, Khiri, Hacène, Pénaranda, Guillaume, Martineau, Agnes, Oulès, Valérie, Cacoub, Patrice

“…Occult hepatitis C infection is regarded as a new entity that should be considered when diagnosing patients with a liver disease of unknown origin. Using an…”
Get full text

Multidisciplinary approach for the treatment of 1155 HCV/HCV-HIV co-infected patients by Isabelle Ravaux, Albert Darque, Amélie Ménard, Catherine Dhiver, Philippe Halfon, Thierry Allègre, Patrick Philibert, Christelle Tomei, Philippe Colson, Rolande Cohen, Laurence Pellissier, Sylvie Brégigeon, Malika Mokhtari, Jacques Moreau, Marie-Josephe Soavi, Caroline Solas, Isabelle Poizot-Martin, Bernard Castan, Valérie Oulès, Marc Bourlière, Isabelle Portal, Danielle Botta-Fridlund

Get full text

Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road? by Bourlière, Marc, Pietri, Olivia, Castellani, Paul, Oules, Valérie, Adhoute, Xavier

“…The advent of oral direct-acting antiviral agents (DAAs) has dramatically improved the hepatitis C virus (HCV) treatment landscape in the last 4 years,…”
Get full text

Sorafenib: Experience and Better Manage­ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis by Raoul, Jean-Luc, Adhoute, Xavier, Penaranda, Guillaume, Perrier, Hervé, Castellani, Paul, Oules, Valérie, Bourlière, Marc

“…Background: Sorafenib is the first-line treatment for advanced hepatocellular carcinoma (HCC). The management of its side effects is improving. This study…”
Get full text

Detection of IL28B SNP DNA from buccal epithelial cells, small amounts of serum, and dried blood spots by Halfon, Philippe, Ouzan, Denis, Khiri, Hacène, Pénaranda, Guillaume, Castellani, Paul, Oulès, Valerie, Kahloun, Asma, Amrani, Nolwenn, Fanteria, Lise, Martineau, Agnès, Naldi, Lou, Bourlière, Marc

“…Point mutations in the coding region of the interleukin 28 gene (rs12979860) have recently been identified for predicting the outcome of treatment of hepatitis…”
Get full text

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease by Ratziu, Vlad, Massard, Julien, Charlotte, Frederic, Messous, Djamila, Imbert-Bismut, Françoise, Bonyhay, Luninita, Tahiri, Mohamed, Munteanu, Mona, Thabut, Dominique, Cadranel, Jean François, Le Bail, Brigitte, de Ledinghen, Victor, Poynard, Thierry

“…Liver biopsy is considered as the gold standard for assessing non-alcoholic fatty liver disease (NAFLD) histologic lesions. The aim of this study was to…”
Get full text

Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease by Poynard, Thierry, Ratziu, Vlad, Charlotte, Frederic, Messous, Djamila, Munteanu, Mona, Imbert-Bismut, Françoise, Massard, Julien, Bonyhay, Luninita, Tahiri, Mohamed, Thabut, Dominique, Cadranel, Jean François, Le Bail, Brigitte, de Ledinghen, Victor

“…Liver biopsy is considered the gold standard for assessing histologic lesions of non-alcoholic fatty liver disease (NAFLD). The aim was to develop and validate…”
Get full text

Sofosbuvir as backbone of interferon free treatments by Bourlière, Marc, Oules, Valèrie, Ansaldi, Christelle, Adhoute, Xavier, Castellani, Paul

“…Abstract Sofosbuvir is the first-in-class NS5B nucleotide analogues to be launched for hepatitis C virus (HCV) treatment. Its viral potency, pangenotypic…”
Get full text

Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort by Adhoute, Xavier, Pénaranda, Guillaume, Raoul, Jean-Luc, Pietri, Olivia, Bronowicki, Jean-Pierre, Castellani, Paul, Perrier, Hervé, Monnet, Olivier, Bayle, Olivier, Oules, Valérie, Pol, Bernard, Beaurain, Patrick, Muller, Cyrille, Cassagneau, Pierre, Bourlière, Marc

“…BACKGROUNDConventional transarterial chemoembolization (cTACE) with lipiodol is widely performed in patients with hepatocellular carcinoma (HCC) unsuitable for…”
Get full text

Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching by Adhoute, Xavier, De Matharel, Marie, Mineur, Laurent, Pénaranda, Guillaume, Ouizeman, Dann, Toullec, Clemence, Tran, Albert, Castellani, Paul, Rollet, Armelle, Oules, Valérie, Perrier, Hervé, Si Ahmed, Si Nafa, Bourliere, Marc, Anty, Rodolphe

“…BACKGROUNDStarting a second-line systemic treatment for hepatocellular carcinoma (HCC) is a common situation. The only therapeutic options in France are two…”
Get full text

Chronic hepatitis C: future treatment by Wendt, Astrid, Adhoute, Xavier, Castellani, Paul, Oules, Valerie, Ansaldi, Christelle, Benali, Souad, Bourlière, Marc

“…The launch of first-generation protease inhibitors (PIs) is a major step forward in HCV treatment. However, the major advance is up to now restricted to…”
Get full text

Onset of coeliac disease and interferon treatment by Bourlière, Marc, Oulés, Valérie, Perrier, Hervé, Mengotti, Cécile

Get full text

How to optimize current therapy of HCV genotype 1 infection with boceprevir by Bourlière, Marc, Adhoute, Xavier, Wendt, Astrid, Ansaldi, Christelle, Oules, Valérie, Castellani, Paul

“…Treatment with first generation protease inhibitors (PIs) is a milestone in the history of HCV therapy. Triple therapy with boceprevir (BOC) improves sustained…”
Get full text

A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus by Halfon, Philippe, Bourliere, Marc, Ouzan, Denis, Maor, Yaakov, Renou, Christophe, Wartelle, Claire, Pénaranda, Guillaume, Tran, Albert, Botta, Danielle, Oules, Valérie, Castellani, Paul, Portal, Isabelle, Argiro, Laurent, Dessein, Alain

“…BACKGROUNDRecent studies have suggested that host genetics may be useful for predicting drug response and have supported the recommendation that single…”
Get full text

Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection by Bourlière, Marc, Adhoute, Xavier, Ansaldi, Christelle, Oules, Valérie, Benali, Souad, Portal, Isabelle, Castellani, Paul, Halfon, Philippe

“…Sofsobuvir is the first-in-class NS5B nucleotide inhibitor to be launched as a treatment for the hepatitis C virus (HCV). Its viral potency, pan genotypic…”
Get more information

Future treatment of patients with HCV cirrhosis by Bourlière, Marc, Khaloun, Asma, Wartelle-Bladou, Claire, Oules, Valérie, Portal, Isabelle, Benali, Souad, Adhoute, Xavier, Castellani, Paul

“…Of all hepatitis C virus (HCV) patients, those with cirrhosis are most in need of treatment because of increased morbidity and mortality. Treatment with…”
Get full text

High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy by Moucari, Rami, Ripault, Marie-Pierre, Oulès, Valérie, Martinot-Peignoux, Michèle, Asselah, Tarik, Boyer, Nathalie, Ray, Ahmed El, Cazals-Hatem, Dominique, Vidaud, Dominique, Valla, Dominique, Bourlière, Marc, Marcellin, Patrick

“…Background/Aims To evaluate the efficacy of peginterferon alfa-2b and ribavirin in unselected consecutive patients with chronic hepatitis C, treated outside of…”
Get full text

Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study by de Lédinghen, Victor, Ratziu, Vlad, Causse, Xavier, Bail, Brigitte Le, Capron, Dominique, Renou, Christophe, Pilette, Christophe, Oules, Valérie, Gelsi, Eve, Oberti, Frédéric, Vallet-Pichard, Anaïs, Provost, Nicolas Le, Cadranel, Jean-François

“…In patients with unexplained elevated transaminases, prognosis of the liver disease and factors associated with increased risk of liver fibrosis and…”
Get full text

Mutation rate in hepatitis C virus NS3 protease is not influenced by HIV-1 protease inhibitor therapy by Halfon, Philippe, Bourlière, Marc, Khiri, Hacène, Pénaranda, Guillaume, Martineau, Agnes, Oulès, Valérie, Courcambeck, Jérôme, Philibert, Patrick

“…Limited analysis by population sequencing has been reported for the selection of isolates with mutations within the NS3 protease that confer resistance to the…”
Get full text

Chronic hepatitis C: Treatments of the future by Bourlière, Marc, Khaloun, Asma, Wartelle-Bladou, Claire, Oules, Valérie, Portal, Isabelle, Benali, Souad, Adhoute, Xavier, Castellani, Paul

“…Summary The launch of first-generation protease inhibitors (PIs) was a major step forward in hepatitis C virus (HCV) treatment. However, this major advance…”
Get full text